Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance.
The prognostic significance of IgH/Bcl2 rearrangement in follicular lymphoma (FL) remains contentious; polymerase chain reaction (PCR) methodology and tissue source variability may account for some inconsistencies. As IgH/Bcl2 major breakpoint region (MBR) sequences may be found in normal blood, an MBR+ result by conventional PCR in blood/bone marrow may not indicate FL. To establish tumour MBR status, 190 lymphoid tissue samples with histologically evident FL (and therefore >1% tumour cells) were examined by real-time quantifiable PCR; 50% (95/190) had clonal MBR IgH/Bcl2 (MBR was considered clonal when >1%). Overall survival (median = 11.5 years) of MBR+ and MBR- patients was not significantly different.
Iqbal
Sameena
S
Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, Charterhouse Square, West Smithfield, London EC1M 6BQ, UK.
Jenner
Michael J R
MJ
Summers
Karin E
KE
Davies
Andrew J
AJ
Matthews
Janet
J
Norton
Andrew J
AJ
Calaminici
Maria
M
Rohatiner
Ama Z
AZ
Fitzgibbon
Jude
J
Lister
T Andrew
TA
Goff
Lindsey K
LK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019457:Chromosome Breakage; D005260:Female; D015321:Gene Rearrangement; D005803:Genes, Immunoglobulin; D019254:Genes, bcl-2; D005819:Genetic Markers; D006801:Humans; D008224:Lymphoma, Follicular / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018709:Statistics, Nonparametric; D015996:Survival Rate
D005819:Genetic Markers